XML 25 R12.htm IDEA: XBRL DOCUMENT v3.20.4
Subsequent Events
 3 Months Ended
Dec. 31, 2020
Subsequent Events [Abstract]  
Subsequent Events

Note 6      Subsequent Events

Subsequent to December 31, 2020;

 

a)the Company received $497,931 of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson's Research. The grant will be used to fund a clinical trial in the Company's lead compound, ANAVEX®2-73 for the treatment of Parkinson's disease.

 

b)the Company issued 683,279 shares of common stock under the 2019 Purchase Agreement, including 661,708 shares of common stock for an aggregate purchase price of $6,649,782 and 21,571 commitment shares.

 

c)an aggregate of 1,841,616 shares were sold under the Sales Agreement for gross proceeds of $25,893,861.